RTOG Foundation Study 3523

Status Date:  May 20, 2025  | Status:  Closed to Accrual

RTOG Foundation Study 3523

MOMENTUM-1

A Multicenter, Randomized, Open-Label, Phase II Study of [177Lu] Lu-Dotatate in Adults with Progressive Intracranial Grade 1-3 Meningioma 

Principal Investigators

Principal Investigator (Radiation Oncology): Erik P. Sulman, MD, PhD
Principal Investigator (Neuro-Oncology): Sylvia C. Kurz, MD, PhD

Primary Objective

To evaluate the efficacy of [177Lu] Lu-Dotatate measured by progression-free survival as compared to local standard of care therapy in adults with progressive WHO grade 1-3 meningioma that demonstrate sufficient uptake by [68Ga] Ga-Dotatate PET. 

Patient Population

Adult patients with progressive WHO grade 1-3 meningioma.

Participating Sites

Institution Name City State/Country

Participate in RTOG Research

To participate as an RTOG study investigator, your organization must be part of the RTOG Foundation network. Patients who wish to participate in a study must be under the care of an RTOG participating investigator. For additional information, email info@rtog.org or call 1-215-574-3173.

See our clinical trials